HDV感染的流行病学、发病机制及诊疗进展

王宇; 陈小华; 赵志敏; 黄恺; 刘成海

doi:10.3969/j.issn.1001-5256.2019.03.040

HDV感染的流行病学、发病机制及诊疗进展

DOI: 10.3969/j.issn.1001-5256.2019.03.040

1. 上海中医药大学附属曙光医院肝病研究所
2. 上海市第六人民医院感染科

详细信息

中图分类号: R512.6;R181.3
计量
- 文章访问数: 1548
- HTML全文浏览量: 83
- PDF下载量: 328
- 被引次数: 0
出版历程
- 收稿日期: 2018-09-18
- 出版日期: 2019-03-20

Research advances in epidemiology, pathogenesis, and diagnosis and treatment of hepatitis D virus infection

Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

摘要

摘要: HBV/HDV合并感染可导致肝病进展加速,但由于HDV RNA等检测方法学尚存在一定局限,HDV的流行病学尚不十分清楚; HDV导致HBV/HDV共感染者的发病机制及其治疗措施也需要进一步探讨。通过回顾我国以及其他国家HDV流行病学特征、HDV特异性免疫与基因型发病机制,并总结HDV的检测方法及治疗方法,分析表明现有HDV感染的检测方法敏感度、特异度低,也无标准化检测方法;探究新的HDV感染检测方法,将有助于研发新型有效抗的HDV药物,对提高HDV感染的疗效具有重要意义。
- 肝炎病毒,δ /
- 流行病学 /
- 诊断 /
- 治疗学 /
- 综述
Abstract: Hepatitis B virus ( HBV) /hepatitis D virus ( HDV) co-infection can accelerate the progression of liver diseases, but due to thelimitations of the detection methods for HDV RNA, the epidemiology of HDV remains unclear. Further studies are needed to investigate thepathogenesis of HBV/HDV co-infection caused by HDV and related treatment methods. By reviewing the epidemiological features of HDV, HDV-specific immunity, genotype, and pathogenesis in China and other countries and summarizing HDV detection methods and treatmentmethods, this article shows that current detection methods for HDV infection have low sensitivity and specificity, with a lack of standardizeddetection methods. Exploration of new HDV detection methods will help to develop new and effective anti-HDV drugs, which has great sig-nificance in improving the outcome of HDV infection.
- hepatitis delta virus /
- epidemiology /
- diagnosis /
- therapeutics /
- review

HTML全文

参考文献(52)

[1] CIANCIO A, RIZZETTO M. Chronic hepatitis D at a standstill:Where do we go from here?[J]. Nat Rev Gastroenterol Hep-atol, 2014, 11 (1) :68-71.

[2] BGUELIN C, MORADPOUR D, SAHLI R, et al. Hepatitis del-ta-associated mortality in HIV/HBV-coinfected patients[J].J Hepatol, 2017, 66 (2) :112.

[3] ROMEO R, DEL NE, RUMI M, et al. A 28-year study of thecourse of hepatitis Deltainfection:A risk factor for cirrhosis andhepatocellular carcinoma[J]. Gastroenterol Hepatol, 2009, 136 (5) :1629-1638.

[4] WELLER ML, GARDENER MR, BOGUS ZC, et al. Hepatitisdelta virus detected in salivary glands of Sjgren's syndromepatients and recapitulates a Sjgren's syndrome-like pheno-type in vivo[J]. Pathog Immun, 2016, 1 (1) :12-40.

[5] FARCI P. Delta hepatitis:An update[J]. J Hepatol, 2003, 39 (1) :212-219.

[6] FLODGREN E, BENGTSSON S, KNUTSSON M, et al. Recenthigh incidence of fulminant hepatitis in Samara, Russia:Mo-lecular analysis of prevailing hepatitis B and D virus strains[J]. J Clin Microbiol, 2000, 38 (9) :3311-3316.

[7] RIZZETTO M. Hepatitis D Virus:Introduction and epidemiolo-gy[J]. Cold Spring Harb Perspect Med, 2015, 5:a021576.

[8] HOLMBERG S, WARD J. Hepatitis delta:Seek and ye shallfind[J]. J Infect Dis, 2010, 202 (6) :822-824.

[9] WEDEMEYER H. Re-emerging interest in hepatitis delta:New in-sights into the dynamic interplay between HBV and HDV[J]. JHepatol, 2010, 52 (5) :627-629.

[10] SMEDILE A, LAVARINI C, FARCI P, et al. Epidemiologic pat-terns of infection with the hepatitis B virus-associated delta a-gent in Italy[J]. Am J Epidemiol, 1983, 117 (2) :223-229.

[11] SHADUR B, MACLACHLAN J, COWIE B. Hepatitis D virus inVictoria 2000-2009[J]. Intern Med J, 2013, 43 (10) :1081-1087.

[12] GISH RG, YI DH, KANE S, et al. Coinfection with hepatitis Band D:Epidemiology, prevalence and disease in patients inNorthern California[J]. J Gastroenterol Hepatol, 2013, 28 (9) :1521-1525.

[13] ABBAS Z, JAFRI W, RAZA S. Hepatitis D:Scenario in the A-sia-Pacific region[J]. World J Gastroenterol, 2010, 16 (5) :554-562.

[14] SHEN L, GU Y, SUN L, et al. Development of a hepatitis del-ta virus antibody assay for study of the prevalence of HDV a-mong individuals infected with hepatitis B virus in China[J]. JMed Virol, 2012, 84 (3) :445-449.

[15] LIAO B, ZHANG F, LIN S, et al. Epidemiological, clinical andhistological characteristics of HBV/HDV co-infection:A retro-spective cross-sectional study in Guangdong, China[J].PLo S One, 2014, 9 (12) :e115888.

[16] RIZZETTO M, HOYER B, CANESE MG, et al. Delta agent:Association of delta antigen with hepatitis B surface antigenand RNA in serum of deltainfected chimpanzees[J]. Proc NatlAcad Sci U S A, 1980, 77 (10) :6124-6128.

[17] BONINO F, HEERMANN KH, RIZZETTO M, et al. Hepatitis deltavirus:Protein composition of delta antigen and its hepatitis B virus-derived envelope[J]. J Virol, 1986, 58 (3) :945-950.

[18] GUDIMA S, CHANG J, MORALEDA G, et al. Parameters ofhuman hepatitis delta virus genome replication:The quantity, quality, and intracellular distribution of viral proteins and RNA[J]. J Virol, 2002, 76 (8) :3709-3719.

[19] LEMPP FA, URBAN S. Hepatitis Delta virus:Replication strat-egy and upcoming therapeutic options for a neglected humanpathogen[J]. Viruses, 2017, 9 (7) :172.

[20] GIERSCH K, ALLWEISS L, VOLZ T, et al. Hepatitis delta co-infection in humanized mice leads to pronounced inductionofinnate immune responses in comparison to HBV mono-infec-tion[J]. J Hepatol, 2015, 63 (2) :346-353.

[21] CHAO M, HSIEH SY, TAYLOR J. Role of two forms of hepati-tis delta virus antigen:Evidence for a mechanism of selflimitinggenome replication[J]. J Virol, 1990, 64 (3) :5066-5069.

[22] GLENN JS, WATSON JA, HAVEL CM, et al. Identification of aprenylation site in delta virus large antigen[J]. Science, 1992, 256 (5061) :1331-1333.

[23] KUO MY, GOLDBERG J, COATES L, et al. Molecular cloningof hepatitis delta virus RNA from an infected woodchuck liver:Sequence, structure, and applications[J]. J Virol, 1988, 62 (6) :1855-1861.

[24] SUREAU C, NEGRO F. The hepatitis delta virus:Replicationand pathogenesis[J]. J Hepatol, 2016, 64 (1 Suppl) :s102.

[25] MEI C. RNA recombination in hepatitis delta virus:Implicationsregarding the abilities of mammalian RNA polymerases[J]. Vi-rus Res, 2007, 127 (2) :208-215.

[26] HUGHES SA, WEDEMEYER H, HRRISON PM. Hepatitis deltavirus[J]. The Lancet, 378 (9785) :73-85.

[27] TABAKMAN SM, LAU L, ROBINSON JT, et al. Plasmonic substratesfor multiplexed protein microarrays with femtomolar sensitivity andbroad dynamic range[J]. Nat Commun, 2011, 2 (9) :466.

[28] REGEV A, SCHIFF ER. Clinical features of hepatitis[J]. Se-min Liver Dis, 2012, 32 (3) :228-236.

[29] TAYLOR JM. Viral hepatitis D[J]. Springer US, 2011, 5:589-595.

[30] WRANKE A, HEIDRICH B, ERNST S, et al. Anti-HDV IgM asa marker of disease activity in hepatitis delta[J]. PLo S One, 2014, 9 (7) :e101002.

[31] PASCARELLA S, NEGRO F. Hepatitis D virus:An update[J].Liver Int, 2015, 31 (1) :7-21.

[32] GRIPPON P, RIBIERE O, CADRANEL JF, et al. Long-termdelta antigenaemia without appearance of delta antibody in twoimmunodeficient patients[J]. Lancet, 1987, 329 (8540) :1031-1031.

[33] KODANI M, MARTIN A, MIXSON-HAYDEN T, et al. One-step real-time PCR assay for detection and quantitation ofhepatitis D virus RNA[J]. J Virol Methods, 2013, 193 (2) :531-535.

[34] SMEDILE A, NIRO MG, RIZZETTO M. Detection of serum HDV-RNA by RT-PCR[J]. Methods Mol Med, 2004, 95 (7) :85-93.

[35] WANG Y, GLENN JS, WINTERS MA, et al. A new dual-targetingreal-time RT-PCR assay for hepatitis D virus RNA detection[J].Diagn Microbiol Infect Dis, 2018, 92 (2) :112-117.

[36] YAMASHIRO T, NAGAYAMA K, ENOMOTO N, et al. Quantifica-tion of the levelof hepatitis delta virus RNA in serum, by real-timepolymerase chain reaction, and its possible correlation with theclinical stage of liver disease[J]. J Infect Dis, 2004, 189 (7) :1151-1157.

[37] ROMEO R, FOGLIENI B, CASAZZA G, et al. High serum levels ofHDV RNA are predictors of cirrhosis and liver cancer in patientswith chronic hepatitis delta[J]. PLo S One, 2014, 9 (3) :e92062.

[38] BRICHLER S, LE GAL F, BUTT A, et al. Commercial real-timereverse transcriptase PCR assays can underestimate or fail toquantify hepatitis delta virus viremia[J]. Clin Gastroenterol Hepa-tol, 2013, 11 (6) :734-740.

[39] BATTEGAY M, SIMPSON LH, HOOFNAGLE JH, et al. Eliminationof hepatitis delta virus infection after loss of hepatitis B surface an-tigen in patients with chronic delta hepatitis[J]. J Med Virol, 1994, 44 (4) :389-392.

[40] LUTTERKORT GL, WRANKE A, HENGST J, et al. Viral domi-nance patterns in chronic hepatitis delta determine early responseto interferon alpha therapy[J]. J Viral Hepat, 2018, 25 (11) :1384-1394.

[41] URBAN S. Liver capsule:Entry and entry inhibition of hepatitis Bvirus and hepatitis delta virus into hepatocytes[J]. Hepatology, 2016, 63 (2) :633.

[42] TAVANEZ JP, CUNHA C, SILVA MC, et al. Hepatitis delta virus ri-bonucleoproteins shuttle between the nucleus and the cytoplasm[J]. RNA, 2002, 8 (5) :637-646.

[43] SHELDON J, RAMOS B, TORO C, et al. Does treatment of hepa-titis B virus infection reduce hepatitis delta virus replication in HIV-HBV-HDV coinfected patients?[J]. Antiviral Ther, 2008, 13 (1) :97-102.

[44] REIJNDERS JG, RICKBORST V, SONNEVELD MJ, et al. Kineticsof hepatitis B surface antigen differ between treatment withpeginterferon with and entecavir[J]. J Hepatol, 2011, 54 (3) :449-454.

[45] HEIDRICH B, YURDAYD C, KABAAM G, et al. Late HDV RNArelapse after peginterferon alpha-based therapy of chronic hepa-titis delta[J]. Hepatology, 2014, 60 (1) :87-97.

[46] YURDAYDIN C, BOZKAYA H, ONDER FO, et al. Treatment ofchronic delta hepatitis with lamivudine vs. lamivudine+interferonvs. interferon[J]. J Viral Hepat, 2008, 15 (4) :314-321.

[47] LANFORD RE, GUERRA B, CHAVEZ D, et al. GS-9620, an oralagonist of Toll-like receptor-7, induces prolonged suppressionof hepatitis B virus in chronically infected chimpanzees[J]. Gas-troenterology, 2013, 144 (7) :1508-1517.

[48] ELAZAR M, GLENN JS. Emerging concepts for the treatment ofhepatitis delta[J]. Curr Opin Virol, 2017, 24:55-59.

[49] HUANG J, PANG XQ, XIE DY. Role of DNA recognition receptorsin pathogenic mechanism of hepatitisB[J]. J Clin Hepatol, 2017, 33 (9) :1794-1797. (in Chinese) 黄劲, 庞秀青, 谢冬英. DNA识别受体在乙型肝炎发病机制中的作用[J].临床肝胆病杂志, 2017, 33 (9) :1794-1797.

[50] WINER BY, SHIRVANI-DASTGERDI E, BRAM Y, et al. Preclinicalassessment of antiviral combination therapy in a genetically hu-manized mouse model for hepatitis delta virus infection[J]. SciTransl Med, 2018, 10 (447) :eaap9328.

[51] YURDAYDIN C, IDILMAN R, KALKAN R, et al. A phase 2 dose-optimization study of Lonafarnib with Ritonavir for the treatment ofchronic delta hepatitis-end of treatment results from the LOWRHDV-2 study[J]. J Hepatol, 2017, 66 (1) :33-34.

[52] BAZINET M, PANTEA V, CEBOTARESCU V, et al. Update on thesafety and efficacy of REP 2139 monotherapy and subsequentcombination therapy with pegylated interferon alpha-2a in Cauca-sian patients with chronic HBV/HDV coinfection[J]. J Hepatol, 2016, 64 (2) :s584-s585.

施引文献

资源附件(0)

访问统计